Basal and pentagastrin-stimulated calcitonin cut-off values in diagnosis of preoperative medullary thyroid cancer

Emine KARTAL BAYKAN1,*, Mehmet ERDOĞAN2
1Department of Endocrinology and Metabolism, Erzurum Regional Education and Research Hospital, Erzurum, Turkey
2Department of Endocrinology and Metabolism, Ege University Medical Faculty, İzmir, Turkey

Received: 21.03.2020 • Accepted/Published Online: 27.10.2020 • Final Version: 30.04.2021

Background/aim: Medullary thyroid cancer (MTC) originates from parafollicular cells (C cell) and produces calcitonin (CT). Basal serum CT was used in the diagnosis and treatment of MTC. If basal CT level is 100 pg/mL or higher, it is likely to have MTC, but if basal CT level is below 10 pg/mL, the probability of developing thyroid disease is low. In cases with basal CT level between 10–100 pg/mL, pentagastrin-stimulated (PS) CT level is studied to evaluate MTC and C cell hyperplasia (CHH). This study aimed to determine cut-off value for basal and PS peak CT level for diagnosis of MTC.

Materials and methods: We retrospectively reviewed files of patients presented to endocrine outpatient clinic of Ege University, Medicine School, between 2010 and 2019; 176 patients with basal CT level of 10–100 pg/mL and patients with PS test were included to the study.

Results: The receiver operating characteristic curve (ROC) analysis was used to determine cut-off value for basal CT that can discriminate cases with MTC and those with nodular goiter. Cut-off value for basal CT was calculated as 46.5 pg/mL (specificity: 100 %, sensitivity: 74 %). In the ROC analysis for peak PS CT, cut-off value was calculated as 285 pg/mL (specificity: 100 %; sensitivity: 82 %). When peak CT level was > 290 pg/mL in PS test, both specificity and sensitivity for MTC were determined as 100 %. The PS peak CT level > 285 pg/mL was significant for MTC diagnosis while range of 117–274 pg/mL was significant for CHH.

Conclusion: In this study, cut-off value was calculated as 46.5 pg/mL for basal CT, whereas 285 pg/mL for PS peak CT in the diagnosis of preoperative MTC.

Key words: Medullary thyroid cancer, C cell hyperplasia, calcitonin, pentagastrin, cut-off

1. Introduction
The medullary thyroid cancer arises from parafollicular C cells and produces calcitonin (CT). It is a rare cancer accounting for 4%–10% of all thyroid cancers [1]. The MTC is sporadic in 75% while familial in 25 % of cases [2,3]pheochromocytomas, mucosal neuromas, ganglioneuromas of the intestinal tract, and skeletal and ophthalmic abnormalities. It appears both as an inherited disorder and as de novo disease. Sequence analysis of germ-line DNA from MEN 2B patients revealed the existence of the same point mutation in the RET protooncogene in 34 unrelated individuals. This sequence difference was not observed in 93 unaffected individuals, including the normal parents of 14 de novo MEN 2B patients. The mutation (ATG → ACG. The major factor predicting morbidity and mortality is early diagnosis and radical surgery in MTC. The MTC is a highly aggressive malignancy with a 10-years life expectancy of 40%–50% [4,5]using uni- and multivariate analysis. DESIGN AND PATIENTS. Clinical, biological, surgical and epidemiological data on 899 MTC patients, diagnosed between 1952 and 1996, were collected by the French Calcitonin Tumors Study Group (GETC).

Basal serum CT level is used in the diagnosis and follow-up of MTC. The CT is a polypeptide involving 32 amino acids, which is produced by parafollicular C cells of thyroid. If basal CT level is 100 pg/mL or higher, it is likely to have MTC. On the other hand, if basal CT level is below 10 pg/mL, the probability of developing thyroid disease is low [6]. An elevated level of serum calcitonin is a highly sensitive marker for MTC, but it is not especially specific. Also, some studies reported that 10% to 40% of all patients with thyroid nodules associated with high basal levels of calcitonin had MTC [7]calcitonin measurements are mostly useful in the evaluation of tumor size and progression, and as an index of biochemical improvement of medullary thyroid carcinomas. Although measurement

* Correspondence: emnkrtl@hotmail.com
of calcitonin is a highly sensitive method for the detection of medullary thyroid carcinoma, it presents a low specificity for this tumor. Several physiologic and pathologic conditions other than medullary thyroid carcinoma have been associated with increased levels of calcitonin. Several cases of thyroid nodules associated with increased values of calcitonin are not medullary thyroid carcinomas, but rather are related to other conditions, such as hypercalcemias, hypergastrinemias, neuroendocrine tumors, renal insufficiency, papillary and follicular thyroid carcinomas, and goiter. Furthermore, prolonged treatment with omeprazole (> 2-4 months. In cases with basal CT level between 10 and 100 pg/mL, pentagastrin-stimulated CT level is studied to evaluate MTC and C cell hyperplasia (CHH). The pentagastrin-stimulated CT level is highly sensitive in demonstrating C cell disease [8]. There is no definitive data regarding cut-off value for CT level after pentagastrin stimulation test. This study aimed to determine cut-off value for basal and pentagastrin-stimulated peak CT level for diagnosis of MTC.

2. Materials and methods

The protocol was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee (2020/06-73). All participants were informed about the survey.

We retrospectively reviewed files of patients presented to endocrine outpatient clinic of Ege University, Medicine School Overall, between 2010 and 2019; 176 patients with basal CT level of 10-100 pg/mL and pentagastrin stimulation test were included to the study.

2.1. Pentagastrin stimulation tests

All 176 patients underwent calcitonin stimulation testing first with pentagastrin. Pentagastrin was administered as an intravenous(iv) injection of 0.5 μg/kg body weight over 10 s of iv infusion. Blood samples were drawn before the application of the stimulant as well as 1, 2, 3, 5, and 10 min after and were used for the measurement of calcitonin. Peak calcitonin level was considered significant. Patients with secondary causes (renal failure, proton-pump inhibitor use, atrophic gastritis, Hashimoto’s thyroiditis, pseudohypoparathyroidism, hepatic cirrhosis, and hypergastrinemia) of CT elevation were excluded. All patients had undergone thyroid surgery, and postoperative histopathology results were available.

2.2. Calcitonin assay

CT assay was performed using IMMUNITE 1000 chemiluminescence analyzer (Siemens AG, Munich, Germany). Detection limit is 2 to 2,000 pg/mL. Blood samples were drawn basally 1, 2, 3, 5 and 10 min after pentagastrin injection.

2.3. Statistical analysis

We performed all statistical analyses using SPSS for Windows (Version 17.0. Chicago, IL, USA). Unless otherwise stated, results were expressed as mean ± SD. We used the Mann–Whitney U test or independent sample t test between two subject groups, and used the Pearson correlation test or Spearman correlation test, as appropriate. Comparison of multiple groups was made by performing an analysis of variance with Bonferroni correction. Comparison of pretest and posttest results was made as dependent sample test analysis and Wilcoxon signed rank test. The ROC analysis was used to determine whether a continuous variable can be used in the diagnosis. Results are presented with 95% confidence interval. The P value < 0.05 was considered as statistically significant.

3. Results

Based on postoperative histopathology results, there was benign nodular goiter in 122 patients, MTC in 23 patients, CHH in 12 patients and nonMTC thyroid cancer in 19 patients. The patients were stratified into 4 groups.

Of 176 patients included, 84 were women, whereas 92 were men. When sex was assessed among groups, the percentage of patients with female sex was higher in patients with MTC, but no statistically significant difference was found when compared with other groups (Chi-square test P: 0.059). In the other three groups, the percentage of male sex patients was higher (Table 1).

Mean age was 51.79 ± 12.66 (range: 24–83 years). The mean age was significantly lower in CHH Group when compared to remaining groups (p: 0.033) where mean age was comparable but the number of patients in this group was 12 and there were less patients than the other groups (Table 1).

Calcitonin: Mean CT level was 14.53 ± 6.13 (10–43 pg/mL) in benign nodular goiter group, 39.93 ± 28.53 (10–85 pg/mL) in the MTC group, 14.57 ± 3.3 pg/mL (11-18 pg/mL) in CHH and 15.79 ± 4.14 pg/mL (10–23 pg/mL) in nonMTC thyroid cancer group.

Basal CT levels of four groups were compared with bonferroni correction and analysis of variance. It was found that basal CT level was significantly higher in MTC group than remaining groups (P: 0.000). There was no significant difference in basal CT level among CHH, benign nodular goiter and nonMTC thyroid cancer groups (Table 1).

Cut-off value for basal CT was calculated as 46.5 pg/mL with specificity of 100 % and sensitivity of 74 % for MTC diagnosis (Area under Curve [AUC]: 0.720; 95 % CI: 0.027–0.117; P: 0.000). The cut-off level for basal CT was calculated as 46.5 pg/mL in women (sensitivity: 68 %; specificity: 100) (AUC: 0.944; 95 % CI: 0.09–0.103; P: 0.000) and 53 pg/mL in men (sensitivity: 84 %; specificity: 100 %) (AUC: 0.935; 95 %: 0.875–0.995; P: 0.001) (Table 1).
When basal CT level was linked to MTC diagnosis, it was found that MTC was present by 100% when CT level was above 100 pg/mL (Table 2).

**Pentagastrin stimulation test:** The mean peak pentagastrin-stimulated CT level was 46.77 ± 34.14 pg/mL (10-142 pg/mL) in benign nodular goiter group, 459.10 ± 494.37 pg/mL (108 - 1938 pg/mL) in MTC group, 195 ± 51.39 pg/mL (117 - 274 pg/mL) in CHH group and 67.36 ± 47.04 pg/mL (14 - 149 pg/mL) in non-MTC thyroid cancer group.

When pentagastrin-stimulated peak CT levels were compared (bonferroni correction and analysis of variance) among groups, it was found to be significantly higher in MTC group (108 – 1938 pg/mL) than remaining groups (p: 0.000). Pentagastrin-stimulated peak CT level ranged from 117 to 274 pg/mL in CHH group, indicating significant difference between CHH and benign nodular goiter and non-MTC thyroid cancer groups (P: 0.000).

When the dependent sample test was analyzed in the Wilcoxon signed-rank test to compare the results of all groups before and after PG stimulation, the difference was statistically significant. (P: 0.000).

In the ROC analysis for peak pentagastrin-stimulated CT, cut-off value was calculated as 285 pg/mL (specificity: 100%; sensitivity: 82%; AUC: 0.928; 95% CI: 0.0–0.26; P: 0.000). When ROC analysis was performed between MTC and CHH groups, cut-off value for peak CT was calculated as 195 pg/mL (specificity: 100%; sensitivity: 93.8%; AUC: 0.948; 95% CI: 0.0–0.26; P: 0.000). When peak CT level was > 290 pg/mL in pentagastrin stimulation test, both specificity and sensitivity for MTC were determined as 100%.

When the correlation between the peak CT level and MTC was evaluated, the MTC was present at 100% when the peak CT level was > 290 pg/mL (Table 3).

### Discussion
In this study, we determined the basal cut-off value and pentagastrin-stimulated peak CT level for the diagnosis of MTC. Cut-off value for basal CT was calculated as 46.5 pg/mL for MTC diagnosis.

#### Table 1. Data of groups (*P < 0.05*).

| Group               | Gender | Age | N     | Calcitonin          | Pentagastrin stimulation test |
|---------------------|--------|-----|-------|---------------------|------------------------------|
| Benign              | Female | 49.8| 122   | 14.53 ± 6.13 pg/mL  | 46.77 ± 34.14 pg/mL          |
|                     | Male   |     | 59 (%48.4) | 16.4 ± 8.7 pg/mL | 43 ± 28.5 pg/mL             |
|                     |        |     | 63 (%51.6) | 13.6 ± 4.3 pg/mL | 48 ± 36.7 pg/mL             |
| MTC                 | Female | 49.4| 23    | **39.93 ± 28.53 pg/mL** | **459.10 ± 494.37 pg/mL**   |
|                     | Male   |     | 13 (%56.5) | 42 ± 27.6 pg/mL | 485 ± 512 pg/mL             |
|                     |        |     | 10 (%43.5) | 46 ± 32.8 pg/mL | 560 ± 676 pg/mL             |
| CHH                 | Female | 43  | 12    | 14.57 ± 3.3 pg/mL  | 195 ± 51.39 pg/mL           |
|                     | Male   |     | 5 (%41.7) | 14.6 ± 3.2 pg/mL | 193 ± 61 pg/mL              |
|                     |        |     | 7 (%58.3) | 14.5 ± 4.94 pg/mL | 198 ± 24 pg/mL              |
| Non-MTC thyroid cancer | Female | 50.9| 19    | 15.79 ± 4.14 pg/mL | 67.36 ± 47.04 pg/mL         |
|                     | Male   |     | 7 (%36.8) | 13.7 ± 5.1 pg/mL | 60 ± 45 pg/mL               |
|                     |        |     | 12 (%63.2) | 17.1 ± 3.9 pg/mL | 70 ± 51 pg/mL               |

#### Table 2. The relationship between CT level and MTC diagnosis.

| Basal calcitonin | MTC diagnosis |
|------------------|---------------|
| < 10 pg/mL       | 0%            |
| 10-15 pg/mL      | 19.1%         |
| 15-20 pg/mL      | 25.6%         |
| 20-50 pg/mL      | 40.5%         |
| 50-100 pg/mL     | 88.5%         |
| ≥ 100 pg/mL      | 100%          |

#### Table 3. The relationship between PG stimulated CT level and MTC diagnosis.

| Peak Calcitonin | MTC diagnosis |
|-----------------|---------------|
| < 100 pg/mL     | 0%            |
| 100–150 pg/mL   | 41.66%        |
| 150–250 pg/mL   | 70%           |
| 250–275 pg/mL   | 84.6%         |
| 275–290 pg/mL   | 93.8%         |
| > 290 pg/mL     | 100%          |
Calcitonin is the most sensitive tumor marker for MTC and its measurement is used to monitor patients with residual and metastatic MTC [27]. However, CT is not specific for MTC and has no established cut-off value. The sensitivity and the specificity of basal serum CT assays can be improved stimulated CT testing. Stimulated CT testing was historically done by measuring serum CT levels after intravenous administration of calcium and/or pentagastrin. The pentagastrin stimulation test has been used widely for many years to stimulate calcitonin.

In this study, we determined the basal cut-off value for the diagnosis of MTC. The ROC analysis was used to determine cut-off value for basal CT that can discriminate cases with MTC and those with nodular goiter. Cut-off value for basal CT was calculated as 46.5 pg/mL with specificity of 100% and sensitivity of 74%. Both specificity and sensitivity for basal CT > 100 pg/mL were 100%. The cut-off level for basal CT was calculated as 46.5 pg/mL, in women and 53 pg/mL in men.

CT levels are slightly lower in women than in men [28,29] due to the sex dependent differences in lower basal CT levels and to the fact that men have a larger C-cell mass than women [30,31]. CT measurement can vary with assay- and nonassay-dependent factors, and procalcitonin (PCT).

There is limited number of studies which determined cut-off value for basal CT level, reporting different cut-off values (≥ 68 pg/mL, ≥ 46 pg/mL and ≥ 32 pg/mL for men and ≥ 35 pg/mL, ≥ 26 ng/mL and ≥ 18 pg/mL for women) [32–37]. RET gene mutations carriers (n = 14).

The cut-off level of CT to initiate pentagastrin testing remains controversial because basal CT values between 10 and 100 represent a gray zone where true- and false-positive cases overlap [38–42]. The prevalence of MTC was 1.37% and reached 41.1% when the basal CT level was abnormal (3% of the patients. We have performed pentagastrin testing in all patients with CT > 10 pg/mL without losing any of these patients to follow-up.

In this study, we determined cut-off value for pentagastrin-stimulated peak CT level for diagnosis of MTC. In the ROC analysis, cut-off value for pentagastrin-stimulated peak CT level was found to be 285 pg/mL in the diagnosis of MTC. Peak CT level was found to be < 274 pg/mL in cases with CHH. In the literature, there is limited number of studies reporting cut-off value for peak CT level for diagnosis of MTC and peak CT level that discriminates MTC from CHH. Scheuba et al. reported pentagastrin-stimulated peak CT level as 560 ng/mL in the diagnosis of MTC, whereas < 129 pg/mL in CHH [41]. Milone et al. found pentagastrin-stimulated peak CT level as 275 pg/mL for diagnosis of MTC [43].

However, the risk of MTC is very low in the range of 10–15 pg/mL basal CT and CT < 100 pg/mL after pentagastrin stimulation. This fits the upper limit of the normal 100 pg/mL range, as published in the 2004 German consensus proposal. Citation?? Annual follow-
up research recommended in patients with pentagastrin stimulation of aCT between 50 and 100 pg/mL shed new light on this issue. Lowering this threshold for surgery can lead many patients to be directed to unnecessary operations. Therefore, the identification of 100 pg/mL as the therapeutic threshold reflects a clinical agreement that balances overtreatment and undertreatment in these patients [44].

Limitations of our study were retrospective design, absence of data of FNAB results for all patients, absence the data of smoking and body mass index data.

In conclusion, cut-off value was found as 46.5 pg/mL for basal CT level and 285 pg/mL for pentagastrin-stimulated peak CT level in the preoperative diagnosis of MTC. The pentagastrin-stimulated peak CT level > 285 pg/mL was significant for MTC diagnosis, while level of 117-274 pg/mL was significant for CHH.

Acknowledgment
The authors declare that this study received no financial support.

Conflict of interest
The authors do not report any conflict of interest.

Informed consent
Ethics committee approval was received for this study from the Ethics Committee (2020/06-73). Written informed consent was obtained from the patients who participated in this study.

References
1. Cohen R, Campos J-M, Salaün C, Massoud Heshmati H, Kraimps J-L et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism 2000; 85 (2): 919-919. doi:10.1210/jcem.85.2.6556
2. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proceedings of the National Academy of Sciences of the United States of America 1994; 91 (4): 1579-1583. doi:10.1073/pnas.91.4.1579
3. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Molecular Genetics 1993; 2 (7): 851-856. doi:10.1093/hmg/2.7.851
4. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: Results in 899 patients. Clinical Endocrinology 1998; 48 (3): 265-273. doi:10.1046/j.1365-2265.1998.00392.x
5. Costante G, Mergingolo D, Durante C, Bianchi D, Nocera M et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. Journal of Clinical Endocrinology and Metabolism. 2007; 92 (2): 450-455. doi:10.1210/jc.2006-1590
6. Pina G, Dubois S, Murat A, Berger N, Niccoli P et al. Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test? Clinical Endocrinology. 2013;78 (3): 358-364. doi:10.1111/cen.12001
7. Toledo SPA, Lourenço DM, Santos MA, Tavares MR, Toledo RA et al. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics. 2009; 64 (7): 699-706. doi:10.1590/S1807-59322009000700015
8. Guyétant S, Rousselet M-C, Durigon M, Chappard D, Franc B et al. Sex-Related C Cell Hyperplasia in the Normal Human Thyroid: A Quantitative Autopsy Study. The Journal of Clinical Endocrinology & Metabolism. 1997; 82 (1): 42-47. doi:10.1210/jcem.82.1.3684
9. Hazard JB, Hawk WA, Crile G. Medullary (solid) carcinoma of the thyroid—a clinicopathologic entity. Journal of Clinical Endocrinology and Metabolism 1959;19 (1): 152-161. doi:10.1210/jcem-19-1-152
10. Melvin KE, Tashjian AH. The syndrome of excessive thyrococitonin produced by medullary carcinoma of the thyroid. Proceedings of the National Academy of Sciences of the United States of America 1968; 59 (4): 1216-1222. doi:10.1073/pnas.59.4.1216
11. Bergholm U, Adami HO, Telenius-Berg M, Johansson H, Wilander E. Incidence of sporadic and familial medullary thyroid carcinoma in Sweden 1959 through 1981: A nationwide study in 126 patients. Acta Oncologica 1990; 29 (1): 9-15. doi:10.3109/028416900989885
12. Keiser HR, Beaven MA, Doppman J, Wells S, Buja LM. Sipple’s syndrome: medullary thyroid carcinoma, pheochromocytoma, and parathyroid disease. Studies in a large family. NIH conference. Annals of internal medicine 1973; 78 (4): 561-579. doi:10.7326/0003-4819-78-4-561
13. Gharib H, Mcconhey WM, Tiegs RD, Bergstrup EJ, Goellner JR et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clinic Proceedings 1992; 67 (10): 934-940. doi:10.1016/S0025-6196(12)60923-9
14. E K, PH I, AE S, QY D, OH C. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000; 88 (5). doi:10.1002/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z
15. Özgen AG, Hamulu F, Bayraktar F, Yilmaz C, Tüzün M et al. Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid. 1999; 9 (6): 579-582. doi:10.1089/thy.1999.9.579

16. Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism 1994; 78 (4): 826-829. doi:10.1210/jcem.78.4.8157706

17. Niccoli P, Wion-Barbot N, Caron P, Henry JF, De Micco C et al. Interest of routine measurement of serum calcitonin: Study in a large series of thyroidectomized patients. Journal of Clinical Endocrinology and Metabolism 1997; 82 (2): 338-341. doi:10.1210/jcem.82.2.3737

18. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. Journal of Clinical Endocrinology and Metabolism 2004; 89 (1):163-168. doi:10.1210/jc.2003-030550

19. Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhäuser A et al. Routine measurement of plasma calcitonin in nodular thyroid diseases. Journal of Clinical Endocrinology and Metabolism 1997; 82 (5):1589-1593. doi:10.1210/jcem.82.5.3949

20. Borchhardt KA, HörI WH, Sunder-Plassmann G. Reversibility of "secondary hypercalcitoninemia" after kidney transplantation. American Journal of Transplantation. 2005; 5 (7): 1757-1763. doi:10.1111/j.1600-6143.2005.00908.x

21. Bevilacqua M, Dominguez LJ, Righini V, Valdes V, Vago T et al. Dissimilar PTH, gastrin, and calcitonin responses to oral calcium and peptones in hypocalciuric hypercalcemia, primary hyperparathyroidism, and normal subjects: A useful tool for differential diagnosis. Journal of Bone and Mineral Research 2006; 21 (3): 406-412. doi:10.1359/JBMR.051210

22. Schuetz M, Duan H, Wahl K, Pirich C, Antoni A et al. T lymphocyte cytokine production patterns in hashimoto patients with elevated calcitonin levels and their relationship to tumor initiation. Anticancer Research 2006; 26 (6B): 4591-4596.

23. Pratz KW, Ma C, Aubry M-C, Vrtiska TJ, Erlichman C. Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated verner-morisson syndrome. Mayo Clinic Proceedings 2005; 80 (1): 116-120. doi:10.1016/S0025-6196(11)62968-6

24. Shi X, Liu R, Basolo F, Giannini R, Shen X et al. Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. The Journal of Clinical Endocrinology & Metabolism 2016; 101 (1): 264-274. doi:10.1210/jc.2015-2917

25. Machens A, Haederle J, Holzhausen HJ, Thomusch O, Schneyer U et al. Differential diagnosis of calcitonin-secreting neuroendocrine carcinoma of the foregut by pentagastrin stimulation. Langenbeck's Archives of Surgery 2000; 385 (6): 398-401. doi:10.1007/s004230000169

26. Erdogan MF, Gursoy A, Kulaksizoglu M. Long-term effects of elevated gastrin levels on calcitonin secretion. Journal of Endocrinological Investigation. 2006; 29 (9): 771-775. doi:10.1007/BF03347369

27. Perros P, Boelaert K, Colley S, Evans C, Evans RM et al. Guidelines for the management of thyroid cancer. Clinical Endocrinology 2014; 81(SUPPL. 1):1-122. doi:10.1111/cen.12515

28. d’Herbomez M, Caron P, Bauters C, Cao C Do, Schlienger JL et al. Reference range of serum calcitonin levels in humans: Influence of calcitonin assays, sex, age, and cigarette smoking. European Journal of Endocrinology 2007; 157 (6): 749-755. doi:10.1530/EJE-07-0566

29. Guyéant S, Rousselet M-C, Bauters C, Cao C Do, Schlienger JL et al. Sex-Related C Cell Hyperplasia in the Normal Human Thyroid: A Quantitative Autopsy Study. The Journal of Clinical Endocrinology & Metabolism 1997; 82 (1): 42-47. doi:10.1210/jcem.82.1.3684

30. Basuyau JP, Mallet E, Leroy M, Brunelle P. Reference intervals for serum calcitonin in men, women, and children. Clinical Chemistry 2004; 50 (10):1828-1830. doi:10.1373/clinchem.2003.026963

31. Kratzsch J, Petzold A, Raue F, Reinhardt W, Bröcker-Preuß M et al. Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. Clinical Chemistry. 2011; 57 (3): 467-474. doi:10.1373/clinchem.2010.151688

32. Colombo C, Verga U, Mian C, Ferrero S, Perrino M et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2012; 97 (3): 905-913. doi:10.1210/jc.2011-2033

33. Doyle P, Düren C, Nerlich K, Verburg FA, Grelle I et al. Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults. Journal of Clinical Endocrinology and Metabolism 2009; 94 (8): 2970-2974. doi:10.1210/jc.2008-2403

34. Russo M, Scollo C, Padova G, Vigneri R, Pellegriti G. Cardiac arrest after intravenous calcium administration for calcitonin stimulation test. Thyroid 2014; 24 (3): 606-607. doi:10.1089/thy.2013.0394

35. Mian C, Perrino M, Colombo C, Cavedon E, Pennelli G et al. Refining calcium test for the diagnosis of medullary thyroid cancer: Cutoffs, procedures, and safety. Journal of Clinical Endocrinology and Metabolism 2014; 99 (5): 1656-1664. doi:10.1210/jc.2013-4088

36. Niederle MB, Scheba C, Gessl A, Li S, Koperek O et al. Calcium-stimulated calcitonin - The "new standard" in the diagnosis of thyroid C-cell disease Clinically relevant gender-specific cut-off levels for an "old test." Biochemia Medica 2018; 28 (3). doi:10.11613/BM.2018.030710
37. Rink T, Truong PN, Schroth HJ, Diener J, Zimny M et al. Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease. Thyroid. 2009; 19 (4): 327-332. doi:10.1089/thy.2008.0102

38. Niccoli P, Wion-Barbot N, Caron P, Henry JF, De Micco C et al. Interest of routine measurement of serum calcitonin: Study in a large series of thyroidectomized patients. Journal of Clinical Endocrinology and Metabolism 1997; 82 (2): 338-341. doi:10.1210/jcem.82.2.3737

39. Elisei R. Routine serum calcitonin measurement in the evaluation of thyroid nodules. Best Practice and Research: Clinical Endocrinology and Metabolism 2008; 22 (6): 941-953. doi:10.1016/j.beem.2008.09.008

40. Hodak SP, Burman KD. Editorial: The Calcitonin Conundrum - Is it time for routine measurement of serum calcitonin in patients with thyroid nodules? Journal of Clinical Endocrinology and Metabolism. 2004; 89 (2): 511-514. doi:10.1210/jc.2003-031983

41. Dietlein M, Wieler H, Schmidt M, Schwab R, Goretzki PE et al. [Routine measurement of serum calcitonin in patients with nodular thyroid disorders?]. Nuklearmedizin Nuclear medicine 2008; 47 (2): 65-72. doi:10.3413/nukmed-0125

42. Scheuba C, Kaserer K, Weinhäusl A, Pandev R, Kaider A et al. Is medullary thyroid cancer predictable? A prospective study of 86 patients with abnormal pentagastrin tests. Surgery 1999; 126 (6): 1089-1096. doi:10.1067/msy.2099.102268

43. Milone F, Ramundo V, Chiofalo MG, Severino R, Paciolla I et al. Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. Clinical Endocrinology 2010; 73 (1): 85-88. doi:10.1111/j.1365-2265.2009.03759.x

44. Karges W, Dralle H, Ruaf F, Mann K, Reiners C et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: german evidence-based consensus recommendation. Experimental and Clinical Endocrinology and Diabetes 2004; 112 (1): 52-58. doi:10.1055/s-2004-815727